UNSPSC 51263145: Alprenolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2502C2OIRK, chemically known as 2-propanol, 1-(o-allylphenoxy)-3-(isopropylamino)-, hydrochloride but more generally known as alprenolol hydrochloride, which bears US NIH Compound Identifier 66368. European Medicines Agency schedules Alprenolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00378MIG.

Most nations, for tariff and trade purposes, schedule alprenolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ALPRENOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Alprenolol hydrochloride bears US NLM identifiers UMLS ID C0282044 and NCI Concept Code C81651. SMILES: CC(C)NCC(COC1CCCCC1CC=C)O.CL.

UNSPSC 51263145 Alprenolol hydrochloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health-service items procured by public health agencies, though the recent opportunities tagged to this code show minimal alignment with alprenolol specifically. The two recent solicitations in the dataset—Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs—address broader pharmaceutical procurement and supply-chain management rather than this specific beta-blocker formulation. State and local health departments and human services agencies are the primary issuing bodies under codes in this pharmaceutical family, typically procuring medications and related delivery or deactivation systems to support community health, emergency response, and pharmacy benefit programs.

Geographic activity centers on Florida and Texas based on the recent opportunities, with Seminole County seeking quarterly deliveries of naloxone units and deactivation systems through an IFB with a response deadline of July 26, 2023, and the Texas HHS Commission gathering market intelligence on direct pharmaceutical contracting models through an RFI posted April 3, 2026. The code shows limited recent activity specifically aligned to alprenolol hydrochloride itself; the tagged opportunities reflect state and local procurement of pharmaceutical products more broadly, suggesting this particular commodity code may see infrequent direct solicitation or that agencies tagging pharmaceutical purchases do not consistently apply commodity-level specificity in their notice classification. Business developers pursuing this code should monitor health department and HHS agency RFPs and RFQs for pharmaceutical procurement, though the recent record indicates limited volume in this narrow formulation category.